Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) on Tuesday, soared 6.06% from the previous trading day, before settling in for the closing price of $1.32. Within the past 52 weeks, ZNTL’s price has moved between $1.01 and $4.44.
Healthcare Sector giant saw their annual sales slid by -12.89% over the last five years. The company achieved an average annual earnings per share of 14.34%. With a float of $59.23 million, this company’s outstanding shares have now reached $72.25 million.
Zentalis Pharmaceuticals Inc (ZNTL) Insider Activity
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Zentalis Pharmaceuticals Inc is 17.89%, while institutional ownership is 74.77%. The most recent insider transaction that took place on Apr 30 ’25, was worth 29,373. In this transaction Director of this company bought 21,000 shares at a rate of $1.40, taking the stock ownership to the 281,192 shares. Before that another transaction happened on Feb 06 ’25, when Company’s Chief Medical Officer bought 20,000 for $2.28, making the entire transaction worth $45,656. This insider now owns 36,629 shares in total.
Zentalis Pharmaceuticals Inc (ZNTL) Earnings and Forecasts
As on 12/31/2024, Multinational firm has announced its last quarter scores, in which it reported -0.61 earnings per share (EPS) for the period topping the consensus outlook (set at -0.68) by 0.07. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.63 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 14.34% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 11.41% during the next five years compared to -12.89% drop over the previous five years of trading.
Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) Trading Performance Indicators
Zentalis Pharmaceuticals Inc (ZNTL) is currently performing well based on its current performance indicators. A quick ratio of 7.76 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.55.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.08, a number that is poised to hit -0.48 in the next quarter and is forecasted to reach -1.88 in one year’s time.
Technical Analysis of Zentalis Pharmaceuticals Inc (ZNTL)
Analysing the last 5-days average volume posted by the [Zentalis Pharmaceuticals Inc, ZNTL], we can find that recorded value of 0.75 million was lower than the volume posted last year of 1.1 million. As of the previous 9 days, the stock’s Stochastic %D was 28.62%.
During the past 100 days, Zentalis Pharmaceuticals Inc’s (ZNTL) raw stochastic average was set at 29.35%, which indicates a significant decrease from 31.18% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.1034 in the past 14 days, which was lower than the 0.1063 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.5449, while its 200-day Moving Average is $1.5574. Now, the first resistance to watch is $1.4567. This is followed by the second major resistance level at $1.5133. The third major resistance level sits at $1.6167. If the price goes on to break the first support level at $1.2967, it is likely to go to the next support level at $1.1933. Should the price break the second support level, the third support level stands at $1.1367.
Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) Key Stats
Market capitalization of the company is 95.37 million based on 72,135K outstanding shares. Right now, sales total 67,430 K and income totals -165,840 K. The company made 0 K in profit during its latest quarter, and -48,280 K in sales during its previous quarter.
